Drug Profile
DS 8312
Alternative Names: DS8312Latest Information Update: 14 May 2016
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertriglyceridaemia
Most Recent Events
- 18 May 2015 Phase-I clinical trials in Hypertriglyceridaemia in Japan (unspecified route)